Latest From Theratechnologies Inc.
Companies pleased at gaining an EU accelerated assessment for a product should be aware that the agency offers no guarantee that they will get to keep it. Novartis’s Zolgensma is one of seven drugs whose review the EMA has taken off the fast track.
It’s hard enough in the first place for companies to persuade the European Medicines Agency that their planned marketing authorization application should be fast-tracked. Many are also finding that after accelerated assessment is granted, it is taken away during the actual review.
- Large Molecule
- Therapeutic Areas
- Infectious & Viral Diseases
- North America
- Parent & Subsidiaries
- Theratechnologies Inc.
- Senior Management
Luc Tanguay, Pres. & CEO
Philippe Dubuc, SVP, CFO
Lyne Fortin, SVP, Chief Commercial Officer
Christian Marsolais, PhD, SVP, CMO
- Contact Info
Phone: (514) 366-7800
2015 Peel Street 5th Fl.
Montréal, H3A 1T8
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.